Progression-free survival was analysed by the identical methodology as that reported in the primary assessment;1 hazard ratios (HR) were derived from stratified Cox regression models, and Mantel-Haenszel stratified log-rank tests (stratification factors were haemoglobin men, <=130 g/L and >130 g/L; women, <=115 g/L and >115 g/L and corrected serum calcium >=2·5 mmol/L and <2·5 mmol/L) were used to calculate p values. RJM reports personal fees from Pfizer, Novartis, Eisai, Genentech, Bristol-Myers Squibb, and GlaxoSmithKline (GSK), during the conduct of the study. Lenvatinib plus everolimus (n=51) Lenvatinib (n=52) Everolimus (n=50) Progression-free survival Progression events 24 (47%) 33 (63%) 29 (58%) 6 months 74% (57-85) 64% (48-76) 43% (26-58) 12 months 52% (34-67) 32% (19-47) 19% (7-36) Objective response Best overall response Complete 1 (2%) 1 (2%) 0 Partial 17 (33%) 19 (37%) 0 Stable disease 24 (47%) 22 (42%) 40 (80%) Progressive disease 2 (4%) 4 (8%) 4 (8%) Not evaluated...